160 Health International (HKG:2656) narrowed its attributable loss to 73 million yuan in 2025 from 107.7 million yuan a year prior, according to a Friday Hong Kong bourse filing.
The Chinese pharmaceutical and healthcare product wholesaler's loss per share stood at 0.24 yuan, compared with 0.37 yuan in the previous fiscal year.
Revenue was 651.9 million yuan in the year, up 5% from 620.7 million yuan in the prior-year period.
The higher revenue was driven by a positive performance of the company's digital healthcare and wellness solutions and sale of pharmaceutical and healthcare products.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.